vs

Side-by-side financial comparison of AVADEL PHARMACEUTICALS PLC (AVDL) and OR Royalties Inc. (OR). Click either name above to swap in a different company.

AVADEL PHARMACEUTICALS PLC is the larger business by last-quarter revenue ($77.5M vs $46.7M, roughly 1.7× OR Royalties Inc.).

Avadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

OR Royalties Inc. is a Canadian company that holds royalties in gold, silver and diamond mines, principally in the form of net smelter returns and streams.Like its predecessor company, Osisko Mining, it is headquartered in Montreal, Quebec, with shares listed on the Toronto Stock Exchange and the New York Stock Exchange.

AVDL vs OR — Head-to-Head

Bigger by revenue
AVDL
AVDL
1.7× larger
AVDL
$77.5M
$46.7M
OR

Income Statement — Q3 FY2025 vs Q2 FY2022

Metric
AVDL
AVDL
OR
OR
Revenue
$77.5M
$46.7M
Net Profit
$20.0K
Gross Margin
Operating Margin
2.5%
Net Margin
0.0%
Revenue YoY
54.9%
Net Profit YoY
100.8%
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVDL
AVDL
OR
OR
Q3 25
$77.5M
Q2 25
$68.1M
Q1 25
$52.5M
Q4 24
$50.4M
Q3 24
$50.0M
Q2 24
$41.5M
Q1 24
$27.2M
Q4 23
$19.5M
Net Profit
AVDL
AVDL
OR
OR
Q3 25
$20.0K
Q2 25
$9.7M
Q1 25
$-4.9M
Q4 24
$-5.0M
Q3 24
$-2.6M
Q2 24
$-13.8M
Q1 24
$-27.3M
Q4 23
$-28.8M
Gross Margin
AVDL
AVDL
OR
OR
Q3 25
Q2 25
90.7%
Q1 25
89.4%
Q4 24
90.5%
Q3 24
87.7%
Q2 24
93.3%
Q1 24
94.4%
Q4 23
96.4%
Operating Margin
AVDL
AVDL
OR
OR
Q3 25
2.5%
Q2 25
13.0%
Q1 25
-5.7%
Q4 24
-6.5%
Q3 24
-0.7%
Q2 24
-30.7%
Q1 24
-95.8%
Q4 23
-128.0%
Net Margin
AVDL
AVDL
OR
OR
Q3 25
0.0%
Q2 25
14.2%
Q1 25
-9.4%
Q4 24
-10.0%
Q3 24
-5.2%
Q2 24
-33.3%
Q1 24
-100.6%
Q4 23
-148.0%
EPS (diluted)
AVDL
AVDL
OR
OR
Q3 25
$0.00
Q2 25
$0.10
Q1 25
$-0.05
Q4 24
$-0.04
Q3 24
$-0.03
Q2 24
$-0.14
Q1 24
$-0.30
Q4 23
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVDL
AVDL
OR
OR
Cash + ST InvestmentsLiquidity on hand
$91.6M
Total DebtLower is stronger
$222.8M
Stockholders' EquityBook value
$98.2M
$1.3B
Total Assets
$199.4M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVDL
AVDL
OR
OR
Q3 25
$91.6M
Q2 25
$81.5M
Q1 25
$66.5M
Q4 24
$73.8M
Q3 24
$65.8M
Q2 24
$71.4M
Q1 24
$88.8M
Q4 23
$105.1M
Stockholders' Equity
AVDL
AVDL
OR
OR
Q3 25
$98.2M
Q2 25
$90.7M
Q1 25
$74.1M
Q4 24
$73.8M
Q3 24
$74.7M
Q2 24
$70.3M
Q1 24
$78.4M
Q4 23
$87.7M
Total Assets
AVDL
AVDL
OR
OR
Q3 25
$199.4M
Q2 25
$187.2M
Q1 25
$167.9M
Q4 24
$164.2M
Q3 24
$158.3M
Q2 24
$157.5M
Q1 24
$167.9M
Q4 23
$164.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVDL
AVDL
OR
OR
Operating Cash FlowLast quarter
$22.2M
Free Cash FlowOCF − Capex
$22.2M
FCF MarginFCF / Revenue
28.7%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1110.25×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVDL
AVDL
OR
OR
Q3 25
$22.2M
Q2 25
$12.7M
Q1 25
$-8.2M
Q4 24
$7.9M
Q3 24
$-6.9M
Q2 24
$-18.2M
Q1 24
$-29.7M
Q4 23
$-28.0M
Free Cash Flow
AVDL
AVDL
OR
OR
Q3 25
$22.2M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
FCF Margin
AVDL
AVDL
OR
OR
Q3 25
28.7%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
Capex Intensity
AVDL
AVDL
OR
OR
Q3 25
0.0%
Q2 25
Q1 25
Q4 24
Q3 24
0.0%
Q2 24
Q1 24
Q4 23
Cash Conversion
AVDL
AVDL
OR
OR
Q3 25
1110.25×
Q2 25
1.31×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons